Marker Therapeutics Inc (MRKR)

[microcapbiotech]

Here is the link for the breast cancer lady:

https://www.cbsnews.com/news/tecentriq-immunotherpy-triple-negative-breast-cancer-shows-promise/

I believe she was given Tecentriq, also called Atezolizumab, made by Genentech/Roche.

Atezolizumab blocks the interaction of PD-L1 with programmed cell death protein 1 (PD-1) and CD80 receptors (B7-1Rs). PD-L1 can be highly expressed on certain tumors, which is thought to lead to reduced activation of immune cells (cytotoxic T-cells in particular) that might otherwise recognize and attack the cancer. Inhibition of PD-L1 by atezolizumab can remove this inhibitor effect and thereby engender an anti-tumor response. It is one of several ways to block inhibitory signals related to T-cell activation, a more general strategy known as "immune checkpoint inhibition."